

## Dravet Syndrome UK's Professional

Les In person at Pullman Hotel, London St Pancras

▶ Live-stream online

## Friday 14th November 2025

Timing	Session title	Presenter(s)
08.00-09.00	Registration and Arrivals (In-person and online)	Dravet Syndrome UK team
09.00-09.05	Welcome and introductions	Professor Helen Cross OBE (Chair)
09.05-9.30	50 years of Dravet Syndrome research – key learnings and implications for other Developmental and Epileptic Encephalopathy	Professor Helen Cross OBE (Chair)
09.30-9.50	Diagnosing Dravet Syndrome – how, why and when	Professor Andreas Brunklaus
09.50-10.10	Never too late: benefits of diagnosis and (re)testing in adults	Professor Sanjay Sisodiya
10.10-10.30	Supporting families after diagnosis	Neil Williamson
10.30-10.50	FIRST Q&A	Panel chaired by Professor Helen Cross OBE
10.50-11.00	BREAK	
11.00-11.20	Comorbidities and the SCN1A Horizons: what we've learnt so far	Dr Amy McTague
11.20-11.40	Cognitive and behavioural insights from Horizons' neurodevelopmental assessments	Dr Stewart Rust & Adrianna Swindler
11.40-12.00	Comorbidities in adults: understanding the true burden	Dr Lisa Clayton
12.00-12.30	Second Q&A	Panel chaired by Professor Helen Cross OBE
12.30-1.15	LUNCH	
1.15-1.45	Dravet Syndrome UK research: current perspectives and future priorities	Dravet Syndrome UK's Chief Scientific Officer Dr Lisa Clayton Dr Jenna Carpenter
1.45-2.15	Anti-seizure therapies in Dravet Syndrome: current and emerging treatments	Professor Sameer Zuberi
2.15-2.30	BREAK	
2.30-3.15	Disease modifying treatments: latest data and future expectations	Professor Helen Cross OBE (Chair), Professor Andreas Brunklaus & Dr Archana Desurkar
3.15-3.45	FINAL Q&A	Panel chaired by Professor Helen Cross OBE
3.45-4.00	WRAP UP AND CLOSE	Professor Helen Cross OBE

Professor Helen Cross OBE and Galia Wilson

## **BOOK YOUR TICKETS AT:** www.dravet.org.uk/event/dsuk-conference-professional-day/

This independent meeting is supported by unrestricted educational grants from multiple organisations including Biocodex, Encoded Therapeutics and Stoke Therapeutics. These organisations have had no involvement in the development of the conference, or any of its content.